NAUTIKA1: A Multicenter Phase II Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients with Resectable Stages IB-III Non-Small Cell Lung Cancer

Brief description of study

Study ML41591, is an umbrella trial that will evaluate the efficacy and safety of targeted therapies in patients with resectable Stage IA2, IB, II, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors harboring selected molecular alterations as determined in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. In this protocol, "study treatment" refers to treatments assigned to patients as part of this study, based on their molecular alterations (i.e., alectinib; entrectinib, and vemurafenib plus cobimetinib, given as a neoadjuvant and adjuvant treatment).


Clinical Study Identifier: s19-00730
ClinicalTrials.gov Identifier: NCT04302025
Principal Investigator: Elaine Shum.
Other Investigators: Stephanie H. Chang, Samantha VanMaanen, Salman Rafi Punekar, Jessica Wang, Carol M Lee, Jonathan B Kahn, Gabrielle Fridman, Joshua K Sabari, Andre L Moreira, Amie J. Kent, David Mendoza, Natalia Cherkassky, Benjamin Cooper, Avital Benson, Sally Lau, Melissa L Martinez, Vamsidhar Velcheti.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.